



1. Vollenhoven, R. V., et al. Sustainability of Response to Upadacitinib Among Patients with Active Rheumatoid Arthritis Refractory to Biological Disease-Modifying Anti-Rheumatic Drugs. ACR Convergence 2021; Poster 1694.
2. Arthritis Foundation. What is Rheumatoid Arthritis. Available at: <https://www.arthritis.org/about-arthritis/types/rheumatoid-arthritis/what-is-rheumatoid-arthritis.php>. Accessed on July 9, 2019
3. Hunter T, et al. Rheumatology International. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004–2014. April 2017.
4. American College of Rheumatology. Rheumatoid Arthritis. Available at: <https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Rheumatoid-Arthritis>. Accessed on June 7, 2019.
5. Ostrowska, M., Maśliński, W., Prochorec-Sobieszek, M., Nieciecki, M., & Sudół-Szopińska, I. 2018. Cartilage and bone damage in rheumatoid arthritis. *Reumatologia*, 56(2), 111–120. <https://doi.org/10.5114/reum.2018.75523>. Accessed on November 1, 2021.
6. RINVOQ® (upadacitinib) [Package Insert]. North Chicago, Ill.: AbbVie Inc.
7. Burmester G.R., et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet*. 2018 Jun 23;391(10139):2503-2512. doi: 10.1016/S0140-6736(18)31115-2. Epub 2018 Jun 18.
8. A Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis. ClinicalTrials.gov. 2020. Available at: <https://clinicaltrials.gov/ct2/show/NCT02819635>. Accessed: June 2021.
9. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy. ClinicalTrials.gov. 2020. Available at: <https://clinicaltrials.gov/ct2/show/NCT02365649>. Accessed: June 2021.
10. A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis (SELECT-GCA). ClinicalTrials.gov. 2020. Available at: <https://clinicaltrials.gov/ct2/show/NCT03725202>. Accessed: June 2021.
11. A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (SELECT-PsA 2). Clinicaltrials.gov. 2020. Available at: <https://clinicaltrials.gov/ct2/show/NCT03104374>. Accessed: June 2021.
12. A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis (Heads Up). ClinicalTrials.gov. 2020. Available at: <https://clinicaltrials.gov/ct2/show/NCT03738397>. Accessed: June 2021.
13. A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis (SELECT AXIS 2). ClinicalTrials.gov. 2020. Available at: <https://clinicaltrials.gov/ct2/show/NCT04169373>. Accessed: June 2021.
14. A Study to Evaluate the Efficacy and Safety of Upadacitinib in Subjects With Takayasu Arteritis (SELECT-TAK). ClinicalTrials.gov. 2020. Available at <https://clinicaltrials.gov/ct2/show/record/NCT04161898>. Accessed: June 2021.